VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the American Journal of Ophthalmology has published results o…
Author: Business Wire
Eyexora Launches the First Hub-and-Spoke Model for Accelerating Ophthalmology Innovation
NEW YORK–(BUSINESS WIRE)– #Ophthalmology–Eyexora Launches the First Hub-and-Spoke Model for Accelerating Ophthalmology Innovation
NeuraLight and CHDI Foundation Collaborate to Develop Precision Eye Movement Biomarkers for Huntington's Disease
TEL AVIV, Israel–(BUSINESS WIRE)–NeuraLight and CHDI Foundation Collaborate to Develop Precision Eye Movement Biomarkers for Huntington’s Disease
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-…
Eye Health America Expands in Northeast Florida with the Addition of Dr. Janet Betchkal, a Glaucoma Specialist in Jacksonville
JACKSONVILLE, Fla.–(BUSINESS WIRE)– #eyecare–Eye Health America (EHA), a leading integrated eye care platform in the Southeastern United States, is pleased to announce a new partnership with Janet Betchkal, MD, a renowned glaucoma specialist practic…
Tenpoint Therapeutics, Ltd. to Participate in Upcoming Eye Care Conferences
LONDON & SEATTLE–(BUSINESS WIRE)– #ophthalmology–Tenpoint Therapeutics today announced participation in four upcoming eye care conferences.
Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of ASANA gas permeable (GP) lenses. ASANA offers e…
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA–(BUSINESS WIRE)–Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA–(BUSINESS WIRE)–Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab-svoa), presented at the 25th Euretina Congress in…
Samenvatting: OpZira, Inc. gelanceerd om oogheelkundige diagnostiek te bevorderen met een innovatief portfolio van medische hulpmiddelen
MIDDLETOWN, Pa.–(BUSINESS WIRE)–OpZira™, Inc., een vooruitstrevend bedrijf in oogheelkundige medische hulpmiddelen, gebaseerd op een lange geschiedenis van excellent onderzoek, heeft vandaag zijn officiële oprichting aangekondigd. OpZira zet zich in …
Riassunto: OpZira, Inc. lanciata per promuovere la diagnostica oftalmica con un portafoglio di dispositivi medici innovativi
MIDDLETOWN, Pa.–(BUSINESS WIRE)–OpZira™, Inc., azienda di dispositivi medici oftalmici futuristici fondata su una tradizione di eccellenza nella ricerca, oggi ha annunciato la sua formazione ufficiale. OpZira è dedicata a fornire tecnologie innovativ…
Resumen: OpZira, Inc. se lanza para avanzar en el diagnóstico ocular con una innovadora gama de dispositivos médicos
MIDDLETOWN, Pensilvania–(BUSINESS WIRE)–OpZira™, Inc, una empresa de dispositivos médicos oftálmicos con visión de futuro cimentada sobre un legado de excelencia en la investigación, ha anunciado hoy su constitución oficial. OpZira se dedica a ofrece…
OpZira, Inc. lance un portefeuille innovant de dispositifs médicaux pour faire progresser le diagnostic ophtalmique
MIDDLETOWN, Pennsylvanie–(BUSINESS WIRE)–OpZira™, Inc., une société avant-gardiste spécialisée dans les dispositifs médicaux ophtalmiques et fondée sur un héritage d’excellence en recherche, annonce aujourd’hui sa création officielle. OpZira se consa…
OpZira, Inc. will mit innovativem Medizinprodukte-Portfolio die Diagnostik in der Augenheilkunde vorantreiben
MIDDLETOWN, Pennsylvania–(BUSINESS WIRE)–OpZira™, Inc., ein innovatives Unternehmen für ophthalmologische Medizinprodukte, das auf einer Tradition der Spitzenforschung aufbaut, gab heute seine offizielle Gründung bekannt. Das Ziel von OpZira besteht …
LambdaVision Secures NASA Phase 2 InSPA Award to Advance Manufacturing Efforts in Low-Earth Orbit
WOODBRIDGE, Conn.–(BUSINESS WIRE)–LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, has been awarded a National Aeronautics and Space Administ…
LambdaVision Secures NASA Phase 2 InSPA Award to Advance Manufacturing Efforts in Low-Earth Orbit
WOODBRIDGE, Conn.–(BUSINESS WIRE)–LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, has been awarded a National Aeronautics and Space Administ…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…